D.P. Ruiz-Genao , A. González-Quesada , A. Sahuquillo-Torralba , R. Rivera-Díaz , M.A. Descalzo , I. García-Doval , en representación del Grupo Biobadaderm
{"title":"Registro BIOBADADERM de la AEDV: 15 años de aportaciones a la seguridad de los tratamientos para la psoriasis","authors":"D.P. Ruiz-Genao , A. González-Quesada , A. Sahuquillo-Torralba , R. Rivera-Díaz , M.A. Descalzo , I. García-Doval , en representación del Grupo Biobadaderm","doi":"10.1016/j.ad.2024.11.027","DOIUrl":"10.1016/j.ad.2024.11.027","url":null,"abstract":"<div><div>The objective of this article is to collect and describe the most relevant BIOBADADERM findings since its beginning in 2008. BIOBADADERM is a prospective cohort registry whose main aim is to analyze the safety profile of the new systemic therapy for the management of psoriasis. Data included in the registry allowed the publication of numerous articles over the past 15 years (2008-2023). Data from the registry join those obtained from clinical trials regarding safety and efficacy profile. Additionally, it has expanded our knowledge of population groups excluded from clinical trials and in less frequent settings. Collaboration with other registries has given us a few fact-checking answers in smaller groups.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 7","pages":"Pages 764-768"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Managing Painful Digital Ulcers in a Patient Undergoing Hemodialysis","authors":"F. Martins , D. Paula , J. Ferreira","doi":"10.1016/j.ad.2023.09.036","DOIUrl":"10.1016/j.ad.2023.09.036","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 7","pages":"Pages 773-774"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Berna-Rico , J.J. Lluch-Galcera , B. Pérez-García , J. Naharro-Rodríguez , C. Azcárraga-Llobet , J. Company-Quiroga , P. Boixeda
{"title":"[Artículo traducido] Efectividad y seguridad en rosácea de un nuevo dispositivo láser de 532-nm y 1.064-nm con pulsación secuencial variable y enfriamiento por espray criogénico","authors":"E. Berna-Rico , J.J. Lluch-Galcera , B. Pérez-García , J. Naharro-Rodríguez , C. Azcárraga-Llobet , J. Company-Quiroga , P. Boixeda","doi":"10.1016/j.ad.2025.05.001","DOIUrl":"10.1016/j.ad.2025.05.001","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 7","pages":"Pages T781-T783"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Ceravalls , A.M. Giménez-Arnau , V. Expósito-Serrano , N. Fernández Chico , A. Lara Moya , I. Bielsa , P. Ribó , B. Mascaró-Hereza , M. Bonfill-Ortí , J. Spertino , E. Serra , C. Baliu-Piqué , G. Melé-Ninot
{"title":"[Artículo traducido] Redefiniendo la retirada de omalizumab en pacientes con urticaria crónica espontánea: el valor de la optimización y de los biomarcadores de recurrencia","authors":"J. Ceravalls , A.M. Giménez-Arnau , V. Expósito-Serrano , N. Fernández Chico , A. Lara Moya , I. Bielsa , P. Ribó , B. Mascaró-Hereza , M. Bonfill-Ortí , J. Spertino , E. Serra , C. Baliu-Piqué , G. Melé-Ninot","doi":"10.1016/j.ad.2025.05.004","DOIUrl":"10.1016/j.ad.2025.05.004","url":null,"abstract":"<div><h3>Background</h3><div>Patients with chronic spontaneous urticaria frequently relapse after discontinuing omalizumab and require its reintroduction. Although prior optimization might reduce recurrences, there is scarce evidence on this issue. Moreover, predictors of relapse have been identified in non-optimized patients before suspension.</div></div><div><h3>Methods</h3><div>We conducted a multicenter retrospective study with patients who discontinued omalizumab after optimization with a 12-month follow-up. Univariate and multivariate (tree classification method and Cox regression) analyses were performed.</div></div><div><h3>Results</h3><div>A total of 131 patients were included, 32.8% of whom relapsed after 12 months. Relapsed patients had longer disease duration (24.00 vs 11.00 months; <em>p</em> <!-->=<!--> <!-->0.032), quicker response to standard dosage (1.00 vs. 3.00 months; <em>p</em> <!-->=<!--> <!-->0.014), fewer complete responses pre-optimization (83.70% vs 95.50%; <em>p</em> <!-->=<!--> <!-->0.023), and shorter treatment duration at 300<!--> <!-->mg/4 weeks (6 vs 7 months; <em>p</em> <!-->=<!--> <!-->0.035). Multivariate analysis revealed that patients with elevated baseline C-reactive protein (CRP) and low total immunoglobulin E (IgE) who underwent prolonged treatment were more likely to maintain a sustained remission at 12 months.</div></div><div><h3>Conclusion</h3><div>Optimization seems to reduce the relapse rate after discontinuation. The most relevant factors for recurrence are associated with the duration of treatment at different doses of omalizumab, along with the baseline CRP and total IgE levels. To minimize relapse after suspension, a 12-month treatment regimen at 300<!--> <!-->mg/4 weeks followed by an 18-month dose tapering is proposed.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 7","pages":"Pages T675-T683"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G.G. Garriga-Martina, J.A. Suárez-Pérez, E.A. Martínez-García, A. Carmona-Olveira, E. Herrera-Acosta
{"title":"[Translated article] Impact of Dupilumab on Quality of Life, Anxiety, and Depression in Adult Patients With Moderate-to-Severe Atopic Dermatitis and Their Household Members: A Prospective Study","authors":"G.G. Garriga-Martina, J.A. Suárez-Pérez, E.A. Martínez-García, A. Carmona-Olveira, E. Herrera-Acosta","doi":"10.1016/j.ad.2025.05.008","DOIUrl":"10.1016/j.ad.2025.05.008","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 7","pages":"Pages T787-T789"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Ortiz-Lazo , V. Velasco-Tamariz , D. Saceda-Corralo , X. Wortsman
{"title":"Técnicas de imagen en tricología: ecografía, microscopia confocal de reflectancia y tomografía de coherencia óptica","authors":"E. Ortiz-Lazo , V. Velasco-Tamariz , D. Saceda-Corralo , X. Wortsman","doi":"10.1016/j.ad.2024.12.020","DOIUrl":"10.1016/j.ad.2024.12.020","url":null,"abstract":"<div><div>Although invasive techniques such as scalp biopsies and non-invasive techniques such as trichoscopy are commonly used for the diagnosis and management of alopecia, the latter does not always provide enough information on the state of the disease. Currently, we have new non-invasive diagnostic methods to complement the clinical and trichoscopic findings of patients with alopecia; these are high-frequency ultrasound (HFU), ultra-high-frequency ultrasound (UHFU), reflectance confocal microscopy (RCM) and optical coherence tomography (OCT), which are capable of identifying structures under the surface of the scalp, while maintaining the ability to monitor hair shafts.</div><div>This review describes the main features reported with each technique for the different types of alopecia —scarring and non-scarring— with the aim of identifying those parameters that may contribute to clarifying new pathophysiological findings, while adding information to the trichoscopic examination and improving diagnostic processes and monitoring.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 7","pages":"Pages 755-763"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Berna-Rico , J.J. Lluch-Galcera , B. Pérez-García , J. Naharro-Rodríguez , C. Azcárraga-Llobet , J. Company-Quiroga , P. Boixeda
{"title":"Assessing the Safety and Efficacy of a New 532-nm and 1064-nm Laser Device With Variable Sequencing and Cryogen Spray Cooling for Rosacea Treatment","authors":"E. Berna-Rico , J.J. Lluch-Galcera , B. Pérez-García , J. Naharro-Rodríguez , C. Azcárraga-Llobet , J. Company-Quiroga , P. Boixeda","doi":"10.1016/j.ad.2024.01.027","DOIUrl":"10.1016/j.ad.2024.01.027","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 7","pages":"Pages 781-783"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Rivera-Ruiz , A. Gil-Villalba , F.J. Navarro-Triviño
{"title":"[Translated article] Exploring New Horizons in Allergic Contact Dermatitis Treatment: The Role of Emerging Therapies","authors":"I. Rivera-Ruiz , A. Gil-Villalba , F.J. Navarro-Triviño","doi":"10.1016/j.ad.2025.05.016","DOIUrl":"10.1016/j.ad.2025.05.016","url":null,"abstract":"<div><div>The resistant and recalcitrant nature of severe allergic contact dermatitis (ACD) makes treatment challenging. With advances in the understanding of the cellular and molecular pathogenesis of this dermatosis, new therapeutic options are emerging. In particular, the use of biologic drugs such as dupilumab and small molecule inhibitors, such as JAK inhibitors have gained momentum given the cross-cutting inhibition of multiple cytokine actions. This article aims to review the current available data on the use of biologic drugs and small molecule inhibitor drugs in the management of ACD. Results suggest that iJAKs, such as abrocitinib, tofacitinib, upadacitinib, and baricitinib; although biologic drugs, such as dupilumab show significant promise in refractory ACD, more long-term clinical trials are needed to confirm their safety and efficacy profile.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 7","pages":"Pages T731-T739"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Translated article] An Overview of Actinic Keratoses: Understanding Etiology, Diagnosis, and Treatment Approaches","authors":"J. Cañueto , L. Turrión , C. Ferrándiz-Pulido","doi":"10.1016/j.ad.2025.05.015","DOIUrl":"10.1016/j.ad.2025.05.015","url":null,"abstract":"<div><div>Actinic keratoses (AK) are common cutaneous lesions located in skin areas chronically exposed to UV radiation, with the potential of progressing into invasive squamous cell carcinoma (SCC). Since it is not possible to predict which AK lesions will become SCC or when will that happen, treating all AK is generally recommended. There is a wide range of therapies available for AK and new drug approvals have joined the therapeutic armamentarium in recent years. These changes in the available treatments for AK require a review of the scientific evidence available and the current status of AK diagnosis and management in Spain.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 7","pages":"Pages T740-T754"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. González Fernández , L. Prieto-Torres , S.J. Martínez-Domínguez , E. Barriendos Ambroj , M. Ara Martín
{"title":"Índice triglicéridos/glucosa combinado con parámetros antropométricos: una herramienta prometedora para el cribado de EHGNA en los pacientes con psoriasis","authors":"J. González Fernández , L. Prieto-Torres , S.J. Martínez-Domínguez , E. Barriendos Ambroj , M. Ara Martín","doi":"10.1016/j.ad.2025.01.008","DOIUrl":"10.1016/j.ad.2025.01.008","url":null,"abstract":"<div><h3>Background</h3><div>Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent causes of liver disease in our region, with a strong association with metabolic factors, such as obesity and diabetes. Recent studies reported that NAFLD was 1.5-3 times more common in psoriatic patients.</div></div><div><h3>Objectives</h3><div>To calculate the diagnostic validity parameters of the triglyceride/glucose (TyG) index, and its combination with anthropometric parameters [body mass index (BMI), waist circumference (WC), and waist-to-heigh ratio (WHR)], as a non-invasive method for detecting NAFLD in patients with moderate-to-severe psoriasis.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional and single-center study with 149 patients with moderate-to-severe psoriasis. The ROC curves and the area under the curve (AUC) were calculated for the TyG index along with different anthropometric measures, using transient elastography as the reference test. The optimal cut-off point was calculated using Youden's index.</div></div><div><h3>Results</h3><div>The prevalence of NAFLD was 64%. A total of 18% of these patients had significant liver fibrosis. The TyG index with anthropometric parameters showed a significant association with liver steatosis (<em>P</em><.001). The TyG-BMI, TyG-WC, and TyG-WHR indices all showed an AUC>.83, while the TyG-BMI showed the highest AUC (0.852). Results were consistent in sex-based analyses.</div></div><div><h3>Conclusions</h3><div>The TyG index with anthropometric parameters —especially BMI— is an effective method for the initial screening of NAFLD in psoriatic patients.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 7","pages":"Pages 684-691"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}